Modelling the lifetime economic consequences of glaucoma in France

References

• Goldstein H. Magnitude and causes of blindness: sources and limitations of data. In: Freemann JS. Editor. Clinical Ophthalmology, Vol 5 (52). Philadelphia: Lippincott, 1990: 1–10.
   Google Scholar
• Kitazawa Y, Horie T, Aoki S. Untreated ocular hypertension. A long-term prospective study. Arch Ophthalmol 1977;95:1180–1189.
   PubMedGoogle Scholar
• Nizankowska MH, Kaczmarek R. Prevalence of glaucoma in the Wroclaw population. The Wroclaw Epidemiological Study. Ophthalmic Epidemiol 2005;12(6):363–371.
   PubMed Web of Science ®Google Scholar
• Anton A, Andrada MT, Mujica V et al. Prevalence of primary open-angle glaucoma in a Spanish population: the Segovia study. J Glaucoma 2004;13(5):371–376.
   PubMed Web of Science ®Google Scholar
• de Voogd S, Ikram MK, Wolfs RC et al. Incidence of open-angle glaucoma in a general elderly population: the Rotterdam Study. Ophthalmology 2005;112(9):1487–1493.
   PubMed Web of Science ®Google Scholar
• Mukesh BN, McCarty CA, Rait JL, Taylor HR. Five-year incidence of open-angle glaucoma: the visual impairment project. Ophthalmology 2002;109(6):1047–1051.
   PubMed Web of Science ®Google Scholar
• Ekstrom C. Prevalence of open-angle glaucoma in central Sweden. The Tierp glaucoma survey. Acta Ophthalmol Scand 1996;74:107–112.
   PubMedGoogle Scholar
• Kahn HA, Leibowitz HM, Ganley JP et al. The Framingham eye study. I. Outline and major prevalence findings. II. Associations of ophthalmic pathology with single variables previously measured in the Framingham Heart Study. Am J Epidemiol 1977;106:33–41.
   PubMed Web of Science ®Google Scholar
• Quigley HA, Vitale S. Models of open-angle glaucoma prevalence and incidence in the United States. Invest Ophthalmol Vis Sci 1997;38(1):83–91.
   PubMed Web of Science ®Google Scholar
• Topouzis F, Wilson MR, Harris A et al. Prevalence of open-angle glaucoma in Greece: the Thessaloniki Eye Study. Am J Ophthalmol 2007;144(4):511–519.
   PubMedGoogle Scholar
• Friedman DS, Jampel HD, Muñoz B, West SK. The prevalence of open-angle glaucoma among blacks and whites 73 years and older: the Salisbury Eye Evaluation Glaucoma Study. Arch Ophthalmol 2006;124(11):1625–1630.
   PubMedGoogle Scholar
• Armaly MF. Ocular pressure and visual fields: a ten-year follow-up study. Arch Ophthalmol 1969;81:25–44.
   PubMedGoogle Scholar
• Le A, Mukesh BN, McCarty CA, Taylor HR. Risk factors associated with the incidence of open-angle glaucoma: the visual impairment project. Invest Ophthalmol Vis Sci 2003;44(9):3783–3789.
   PubMed Web of Science ®Google Scholar
• Weih LM, Nanjan M, McCarty CA, Taylor HR. Prevalence and predictors of open-angle glaucoma: results from the visual impairment project. Ophthalmology 2001;108(11):1966–1972.
   PubMed Web of Science ®Google Scholar
• Dietelsman I, Vingerling JR, Algra D et al. Primary open-angle glaucoma, intraocular pressure and systemic blood pressure in the general elderly population. Ophthalmology 1995;102:54–60.
   PubMedGoogle Scholar
• Dietelsman I, De Jong PTV, Stolk R et al. Primary open-angle glaucoma, intraocular pressure and diabetes mellitus in the general elderly population. Ophthalmology 1996;103(8):1271–1275.
   PubMedGoogle Scholar
• Tielsch JM, Katz J, Quigley HA et al. Family history and risk of primary open-angle glaucoma. The Baltimore Eye Survey. Arch Ophthalmol 1994;112:69–73.
   PubMed Web of Science ®Google Scholar
• Martin MJ, Sommer A, Gold EB et al. Race and primary open-angle glaucoma. Am J Ophthalmol 1985;58:529–535.
   Google Scholar
• Hattenhauer MG, Johnson DH, Ing HH et al. The probability of blindness from open-angle glaucoma. Ophthalmology 1998;105(11):2099–2104.
   PubMed Web of Science ®Google Scholar
• Ramrattan RS, Wolfs RC, Panda-Jonas S et al. Prevalence and causes of visual field loss in the elderly and associations with impairment in daily functioning: the Rotterdam Study. Arch Ophthalmol 2001;119(12):1788–1794.
   PubMedGoogle Scholar
• Wilson M, Kosoko O, Cowan C et al. Progression of visual field loss in untreated glaucoma patients and glaucoma suspects in St. Lucia, West Indies. Am J Ophthalmol 2002;134(3):399.
   PubMedGoogle Scholar
• Kwon YH, Kim CS, Zimmerman MB et al. Rate of visual field loss and long-term visual outcome in primary open-angle glaucoma. Am J Ophthalmol 2001;132(1):47–56.
   PubMed Web of Science ®Google Scholar
• Katz J. Scoring systems for measuring progression of visual field loss in clinical trials of glaucoma treatment. Ophthalmology 1999;106(2):391–395.
   PubMed Web of Science ®Google Scholar
• Hiller R, Podgor MJ, Sperduto RD et al. High intraocular pressure and survival: the Framingham Studies. Am J Ophthalmol 1999;128(4):440–445.
   PubMedGoogle Scholar
• Kass MA, Heuer DK, Higginbotham EJ et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002;120(6):701–713.
   PubMed Web of Science ®Google Scholar
• The AGIS investigators. The advanced glaucoma intervention study (AGIS): 7. The relationship between control of intra- ocular pressure and visual field deterioration. Am J Ophthalmol 2000;130(4):429–440.
   PubMed Web of Science ®Google Scholar
• Anderson DR. The management of elevated intraocular pressure with normal optic discs and visual fields. Surv Ophthalmol 1977;21:479–489.
   PubMed Web of Science ®Google Scholar
• Fingeret M. Glaucoma medications, glaucoma therapy, and the evolving paradigm. J Am Optom Assoc 1998;69(2):115–121.
   PubMedGoogle Scholar
• Reyes E, Izquierdo NJ, Blasini M. Adverse drugs reactions associated with glaucoma medications. Bol Asoc Med P R 1997;89(4–6):51–55.
   PubMedGoogle Scholar
• Denis P, Lafuma A, Berdeaux G. Medical predictive factors of glaucoma treatment costs. J Glaucoma 2004;13(4):283–290.
   PubMed Web of Science ®Google Scholar
• Oostenbrink JB, Rutten-van Mölken MP, Opdenoordt TS et al. Resource use and costs of patients with glaucoma or ocular hypertension: a one-year study based on retrospective chart review in The Netherlands. J Glaucoma 2001;10(3):184–191.
   PubMedGoogle Scholar
• Oostenbrink JB, Rutten-van Mölken MP, Opdenoordt TS. The treatment of newly diagnosed patients with glaucoma or with ocular hypertension in The Netherlands: an observational study of costs and initial treatment success based on retrospective chart review. Doc Ophthalmol 1999;98(3):285–99.
   PubMedGoogle Scholar
• Kobelt G, Jonsson L, Gerdtham U et al. Direct costs of glaucoma management following initiation of medical therapy. A simulation model based on an observational study of glaucoma treatment in Germany. Graefes Arch Clin Exp Ophthalmol 1998;236(11):811–821.
   PubMed Web of Science ®Google Scholar
• Jonsson B, Krieglstein G. Primary open-angle glaucoma. Differences in International Treatment Patterns and Costs. Oxford: Isis Medical Media, 1999.
   Google Scholar
• Calissendorff BM. Costs of medical and surgical treatment of glaucoma. Acta Ophthalmol Scand 2001;79(3):286–288.
   PubMedGoogle Scholar
• Kobelt-Nguyen G, Gerdtham UG, Alm A. Costs of treating primary open-angle glaucoma and ocular hypertension: a retrospective, observational two-year chart review of newly diagnosed patients in Sweden and the United States. J Glaucoma 1998;7(2):95–104.
   PubMed Web of Science ®Google Scholar
• Kobelt G, Jönsson L. Modeling cost of treatment with new topical treatments for glaucoma. Results from France and the United Kingdom. Int J Technol Assess Health Care 1999;15(1):207–219.
   PubMed Web of Science ®Google Scholar
• Roulland JF, Berdeaux G, Lafuma A. The economic burden of glaucoma and ocular hypertension: implications for patient management. A review. Drug Aging 2005;22(4):315–321.
   PubMedGoogle Scholar
• Baudouin C, Rouland JF, Le Pen C. Changes in medical and surgical treatments of glaucoma between 1997 and 2000 in France. Eur J Ophthalmol 2003;13(Suppl 4):S53–60.
   Google Scholar
• Weinstein MC. The costs of prevention. J Gen Intern Med 1990;5(5 Suppl):S89–92.
   PubMedGoogle Scholar
• Hjelmgren J, Berggren F, Andersson D. Health economics guidelines – similarities, differences and some implications. Value Health 2001;4:225–250.
   PubMedGoogle Scholar
• Nordmann JP, Lafuma A, Pradet S et al. Clinical outcomes of glaucoma treatments over a patient life: a Markov model. J Glaucoma 2005;14(6):463–469.
   PubMed Web of Science ®Google Scholar
• Denis P, Lafuma A, Berdeaux G. Medical outcome of glaucoma therapy from a nationwide representative survey. Clin Drug Investig 2004;24(6):343–352.
   PubMed Web of Science ®Google Scholar
• Kymes S. Clinical outcomes of glaucoma treatment over a patient lifetime: a Markov model (letter). J Glaucoma 2006;15(5):471–472; author reply 472–473.
   PubMedGoogle Scholar
• European Medicines Agency. Available at: http://www.emea.europa.eu/.
   Google Scholar
• Morniche P. L'enquête HID de l'INSEE – Objectifs et schéma organisationnel. Courrier des Statistiques 1997;87,88,7–18.
   Google Scholar
• Ravaud J-F, Letourmy A, Ville I. Identifying the population with disability: the approach of an INSEE survey on daily life and health. Population-E 2002;57(3):529–552.
   Google Scholar
• OECD - Organisation for Economic Co-operation and Development. OECD health data: a comparative analysis of 29 Countries. Credes, 1999; Eco-Santé software, Paris.
   Google Scholar
• Brown MM, Brown GC, Sharma S et al. Utility values associated with blindness in an adult population. Br J Ophthalmol 2001;85:327–331.
   PubMed Web of Science ®Google Scholar
• Sharma S, Brown GC, Brown MM et al. Converting visual acuity to utilities. Can J Ophthalmol 2000;35:267–272.
   PubMed Web of Science ®Google Scholar
• Lafuma A, Brézin A, Lopatriello S et al. Evaluation of non-medical costs associated with visual impairment in four European countries (France, Italy, Germany and the United Kingdom). PharmacoEconomics 2006;24(2):193–205.
   PubMed Web of Science ®Google Scholar
• Auquier P, Auray JP, Berdeaux G et al. French guidelines for the economic evaluation of health care technologies. Methodological recommendations. Work carried out by the Members of the Collège des économistes de la Santé (the French Health Economists Association) under the coordination of émile Lévy and Gérard de Pouvourville. CES, Collège des économistes de la Santé, Paris, September 2004: 1–86. Available at : http://www.ces-asso.org.
   Google Scholar
• Etablissements de soins de longue durée pour personnes âgées, Infos DGAS, n°70, Ministère de la Santé, 2000 Paris.
   Google Scholar
• Morniche P. L'enquête HID de l'INSEE – Objectifs et schéma organisationnel. Courrier des Statistiques 1998;87,88. Paris: INSEE.
   Google Scholar
• Brézin A, Lafuma A, Fagnani F et al. Prevalence and burden of self-reported blindness and low vision for subjects living in institutions: a nation-wide survey. Health Qual Life Outcomes 2005;3(1):27.
   PubMedGoogle Scholar
• Brézin A, Lafuma A, Fagnani F et al. Prevalence and burden of blindness, low vision and visual impairment in institution: a nation-wide survey. Arch Ophthalmol 2005;123(8):1117–1124.
   PubMedGoogle Scholar
• Brézin A, Lafuma A, Fagnani F et al. Blindness, low vision and other handicaps as risk factors of institution. Br J Ophthalmol 2004,88(10):1330–1337.
   PubMed Web of Science ®Google Scholar
• Evans RL. Loneliness, depression and social activity after determination of legal blindness. Psychol Rep 1983;52:603–608.
   PubMed Web of Science ®Google Scholar
• Scott IU, Schein OD, Feuer WJ et al. Emotional distress in patients with retinal disease. Am J Ophthalmol 2001;131(5):548–589.
   Google Scholar
• Legood R, Scuffham P, Cryer C. Are we blind to injuries in the visually impaired? A review of the literature. Inj Prev 2002;8(2):155–160.
   PubMed Web of Science ®Google Scholar
• Cacciatore F, Abete P, Maggi S et al. Disability and 6-year mortality in elderly population. Role of visual impairment. Aging Clin Exp Res 2004;16:382–388.
   PubMed Web of Science ®Google Scholar
• Taylor HR, McCarty CA, Nanjan MB. Vision impairment predicts five-year mortality. Trans Am Ophthalmol Soc 2000;98:91–96.
   PubMedGoogle Scholar
• Krumpaszky HG, Dietz K, Mickler A et al. Mortality in blind subjects. A population-based study on social security files from Baden-Württemberg. Ophthalmologica 1999;213:48–53.
   PubMed Web of Science ®Google Scholar
• Thompson JR, Gibson JM, Jagger C. The association between visual impairment and mortality in elderly people. Age Ageing 1989;18:83–88.
   PubMed Web of Science ®Google Scholar
• Wang JJ, Mitchell P, Simpson JM et al. Visual impairment, age-related cataract, and mortality. Arch Ophthalmol 2001;119:1186–1190.
   PubMed Web of Science ®Google Scholar
• Smith DH, Fenn P, Drummond M. Cost effectiveness of photodynamic therapy with verteporfin for age related macular degeneration: the UK case. Br J Ophthalmol 2004;88(9):1107–1112.
   PubMed Web of Science ®Google Scholar
• Donati G. Cost-effectiveness of photodynamic therapy with verteporfin for choroidal neovascularization in age-related macular degeneration in routine clinical practice in Switzerland. J Fr Ophtalmol 2007;30(8):837–41 [French].
   PubMedGoogle Scholar
• Hurley SF, Matthews JP, Guymer RH. Cost-effectiveness of ranibizumab for neovascular age-related macular degeneration. Cost Eff Resourc Alloc 2008;6:12.
   PubMedGoogle Scholar
• Karnon J, Czoski-Murray C, Smith K et al. A preliminary model based assessment of the cost-utility of a screening programme for early age-related macular degeneration. Health Technol Assess 2008;12(27):iii-iv, ix-124.
   Google Scholar